MCID: PRP036
MIFTS: 45

Peripheral T-Cell Lymphoma malady

Categories: Rare diseases, Cancer diseases, Immune diseases

Aliases & Classifications for Peripheral T-Cell Lymphoma

Aliases & Descriptions for Peripheral T-Cell Lymphoma:

Name: Peripheral T-Cell Lymphoma 38 50 69
Lymphoma T-Cell Peripheral 52

Classifications:



External Ids:

ICD10 33 C84.4

Summaries for Peripheral T-Cell Lymphoma

MalaCards based summary : Peripheral T-Cell Lymphoma, also known as lymphoma t-cell peripheral, is related to post-transplant lymphoproliferative disease and primary cutaneous peripheral t-cell lymphoma not otherwise specified, and has symptoms including pruritus An important gene associated with Peripheral T-Cell Lymphoma is TIA1 (TIA1 Cytotoxic Granule Associated RNA Binding Protein), and among its related pathways/superpathways are RhoGDI Pathway and Tyrosine Kinases / Adaptors. The drugs Beleodaq and Folotyn have been mentioned in the context of this disorder. Affiliated tissues include t cells, b cells and bone, and related phenotypes are Decreased human cytomegalovirus (HCMV) strain AD169 replication and neoplasm

Related Diseases for Peripheral T-Cell Lymphoma

Diseases related to Peripheral T-Cell Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 137)
id Related Disease Score Top Affiliating Genes
1 post-transplant lymphoproliferative disease 27.7 ALK CXCR3 ETV6 FGFR3 GZMB MS4A1
2 primary cutaneous peripheral t-cell lymphoma not otherwise specified 12.5
3 enteropathy-associated t-cell lymphoma 11.5
4 lymphoma 11.1
5 primary cutaneous aggressive epidermotropic cd8+ t-cell lymphoma 10.7
6 b-cell lymphomas 10.4
7 angioimmunoblastic t-cell lymphoma 10.3
8 diffuse large b-cell lymphoma 10.3
9 primary cutaneous gamma/delta-positive t-cell lymphoma 10.3
10 primary cutaneous cd4+ small/medium-sized pleomorphic t-cell lymphoma 10.3
11 leukemia 10.3
12 malignant glioma 10.2 GZMB TIA1
13 alström syndrome 10.2 GZMB TIA1
14 skeletal muscle cancer 10.2 GZMB TIA1
15 tibial adamantinoma 10.2 GZMB TIA1
16 superior limbic keratoconjunctivitis 10.2 GZMB TIA1
17 collagen type iii glomerulopathy 10.2 GZMB TIA1
18 fibrosclerosis of breast 10.2 GZMB TIA1
19 uterine ligament endometrioid adenocarcinoma 10.2 GZMB TIA1
20 linear lichen planus 10.2 GZMB TIA1
21 malignant teratoma 10.2 GZMB TIA1
22 apoa1-associated familial high density lipoprotein deficiency 10.2 ALK NME1
23 cerebral lipidosis 10.2 GZMB TIA1
24 childhood immature teratoma of ovary 10.2 GZMB TIA1
25 nonsyndromic hearing loss and deafness, x-linked 10.1 ALK NME1
26 anaplastic large cell lymphoma 10.1
27 plasmodium ovale malaria 10.1 GZMB TIA1
28 mixed cell type cancer 10.1 GZMB TIA1
29 congenital absence of thigh and lower leg with foot present, bilateral 10.1 ALK CXCR3
30 venezuelan hemorrhagic fever 10.1 CXCR3 GZMB
31 congenital sucrase-isomaltase deficiency with starch and lactose intolerance 10.1 ALK GZMB TIA1
32 macrogyria, pseudobulbar palsy and mental retardation 10.1 ALK GZMB TIA1
33 lip cancer 10.1 ALK GZMB TIA1
34 hypereosinophilic syndrome 10.1
35 hodgkin lymphoma 10.1
36 t-cell leukemia 10.1
37 adult t-cell leukemia 10.1
38 estrogen-receptor negative breast cancer 10.1 ALK TIA1
39 coarctation of aorta 10.1 CXCR3 GZMB TIA1
40 burns 10.0 CXCR3 GZMB
41 composite lymphoma 10.0
42 hyperaldosteronism, familial, type ii 10.0 GZMB MS4A1 TIA1
43 myelofibrosis 10.0
44 hematopoietic stem cell transplantation 10.0
45 hemophagocytic lymphohistiocytosis 10.0
46 hepatitis 10.0
47 vascular hemostatic disease 10.0 ALK FGFR3
48 lethal midline granuloma 9.9
49 adult-onset still's disease 9.9
50 chronic lymphocytic leukemia 9.9

Graphical network of the top 20 diseases related to Peripheral T-Cell Lymphoma:



Diseases related to Peripheral T-Cell Lymphoma

Symptoms & Phenotypes for Peripheral T-Cell Lymphoma

UMLS symptoms related to Peripheral T-Cell Lymphoma:


pruritus

GenomeRNAi Phenotypes related to Peripheral T-Cell Lymphoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased human cytomegalovirus (HCMV) strain AD169 replication GR00248-A 8.92 ALK FGFR3 NME1 SYK

MGI Mouse Phenotypes related to Peripheral T-Cell Lymphoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.02 ALK CXCR3 ETV6 FGFR3 NME1

Drugs & Therapeutics for Peripheral T-Cell Lymphoma

FDA approved drugs:

id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Beleodaq 17 46 BELINOSTAT Spectrum Pharmaceuticals Approved July 2014
2
Folotyn 17 46 PRALATREXATE Allos Therapeutics Approved September 2009
3
Istodax 17 46 ROMIDEPSIN Gloucester Pharmaceuticals Approved November 2009

Drugs for Peripheral T-Cell Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 469)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
2
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
3
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 23214-92-8 31703
4
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1 95058-81-4 60750
5
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 83-43-2 6741
6
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
7
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 53-03-2 5865
8
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
9
Cytarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 147-94-4 6253
10
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-02-2 5743
11
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 33419-42-0 36462
12
Ifosfamide Approved Phase 4,Phase 3,Phase 2,Phase 1 3778-73-2 3690
13
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
14
rituximab Approved Phase 4,Phase 2,Phase 3,Phase 1 174722-31-7 10201696
15
Vindesine Approved Phase 4,Phase 3,Phase 2,Phase 1 59917-39-4, 53643-48-4 40839
16
Asparaginase Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 9015-68-3
17
Daunorubicin Approved Phase 4,Phase 3,Phase 2,Phase 1 20830-81-3 30323
18
Thioguanine Approved Phase 4,Phase 3,Phase 2 154-42-7 2723601
19
Mechlorethamine Approved Phase 4,Phase 3,Phase 1,Phase 2 51-75-2 4033
20
Epirubicin Approved Phase 4,Phase 2,Phase 1 56420-45-2 41867
21
Pegaspargase Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 130167-69-0
22
Cladribine Approved, Investigational Phase 4,Phase 1 4291-63-8 20279
23
Mesna Approved Phase 4,Phase 3,Phase 2,Phase 1 3375-50-6 598
24
Aprepitant Approved, Investigational Phase 4 170729-80-3 151165 6918365
25
Fosaprepitant Approved Phase 4 172673-20-0 219090
26
Vorinostat Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 149647-78-9 5311
27
Infliximab Approved Phase 4 170277-31-3
28
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 59-30-3 6037
29
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 58-05-9 54575, 6560146 143
30
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1 31703
31
Substance P Investigational Phase 4 33507-63-0 44359816
32
Pirarubicin Investigational Phase 4 72496-41-4
33 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
34 Angiogenesis Inhibitors Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
35 Angiogenesis Modulating Agents Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
36 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
37 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
38 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
39 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
40 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1
41 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1
42 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1
43 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
44 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
45 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
46 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
47 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1
48 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
49 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
50 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 658)
id Name Status NCT ID Phase
1 Treatment of Peripheral T-cell Lymphoma Completed NCT01664975 Phase 4
2 Trial for the Treatment of Newly Diagnosed Mature B-Cell Acute Lymphoblastic Leukemia (B-ALL), Burkitt's Non-Hodgkin's Lymphoma (NHL) and Other High-grade Lymphoma in Adults Completed NCT00199082 Phase 4
3 German Multicenter Trial for the Treatment of Newly Diagnosed T-lymphoblastic Lymphoma in Adults Completed NCT00199017 Phase 4
4 Combination Chemotherapy Including Cisplatin, Ifosfamide, Gemcitabine, L-asparaginase, Etoposide and Dexamethasone as Treatment of Newly Diagnosed and Relapsed/Refractory Peripheral T Cell Lymphomas Recruiting NCT03071822 Phase 4
5 A Pralatrexate Study in Asian Patients With Peripheral T-cell Lymphoma After Prior Therapy Recruiting NCT03150602 Phase 4
6 CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL Recruiting NCT02533700 Phase 4
7 A Research Study to Bank Samples for Future Evaluation to Identify Biomarkers That Predispose Crohn's Disease and Ulcerative Colitis Patients to Develop Hepatosplenic T-Cell Lymphoma (HSTCL) Recruiting NCT01804166 Phase 4
8 CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma Recruiting NCT01746992 Phase 4
9 Treatment of Natural Killer/T Cell Lymphoma-I/II Recruiting NCT01501136 Phase 4
10 Treatment of Natural Killer/T Cell Lymphoma-Ⅲ/Ⅳ Recruiting NCT01501149 Phase 4
11 A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin Lymphoma Active, not recruiting NCT01990534 Phase 4
12 Effect of Neurokinin-1 Receptor (NK1R) Antagonism on Pruritus in Patients With Sezary Syndrome Terminated NCT01625455 Phase 4
13 Impact of Vorinostat on Pruritus Signaling Pathways - Merck Study Withdrawn NCT01801670 Phase 4
14 Immunotherapy in Peripheral T Cell Lymphoma - the Role of Alemtuzumab in Addition to Dose Dense CHOP Unknown status NCT00725231 Phase 3
15 Alemtuzumab and CHOP in T-cell Lymphoma Unknown status NCT00646854 Phase 3
16 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3
17 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3
18 Combination Chemotherapy Plus Steroid Therapy in Treating Children With Acute Lymphoblastic Leukemia or Lymphoblastic Non-Hodgkin's Lymphoma Unknown status NCT00003728 Phase 3
19 Combination Chemotherapy in Treating Children With Non-Hodgkin's Lymphoma Unknown status NCT00003423 Phase 3
20 Combination Chemotherapy in Treating Children With Non-Hodgkin's Lymphoma Unknown status NCT00003650 Phase 3
21 Combination Chemotherapy in Treating Children With Anaplastic Large Cell Lymphoma Unknown status NCT00006455 Phase 3
22 Risk-Adjusted Combination Chemotherapy in Treating Young Patients With Acute Lymphoblastic Leukemia Unknown status NCT00764907 Phase 3
23 Two Combination Chemotherapy Regimens in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia Unknown status NCT00707083 Phase 3
24 Treatment of Acute Lymphoblastic Leukemia in Children Unknown status NCT00400946 Phase 3
25 Study About Treatment of Newly Diagnosed Non Cutaneous Peripheral T Cell Lymphoma Completed NCT00970385 Phase 3
26 Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases Completed NCT00438958 Phase 3
27 Itraconazole Compared With Fluconazole to Prevent Infections in Patients Undergoing Peripheral Stem Cell or Bone Marrow Transplantation Completed NCT00003883 Phase 3
28 Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation Completed NCT00014391 Phase 3
29 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3
30 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
31 Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation Completed NCT00004230 Phase 3
32 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3
33 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3
34 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
35 St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer Completed NCT00005805 Phase 3
36 Comparison of Nutritional Supplements in Preventing Weight Loss in Patients With Cancer Completed NCT00053053 Phase 3
37 Stem Cell Transplantation for Patients With Hematologic Malignancies Completed NCT00152139 Phase 3
38 Laboratory-Treated Donor Bone Marrow in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer Completed NCT00265837 Phase 3
39 Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications Completed NCT00799461 Phase 3
40 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
41 Chronic Graft-versus-host Disease (cGvHD) Prophylaxis With or Without ATG Prior to Stem Cell Transplantation (SCT) From HLA-identical Siblings in Patients With Acute Leukemia Completed NCT00678275 Phase 3
42 Bone Marrow Transplantation in Treating Patients With Leukemia, Myelodysplasia, or Lymphoblastic Lymphoma Completed NCT00003187 Phase 2, Phase 3
43 Comparison of Two Combination Chemotherapy Regimens in Treating Adults With Previously Untreated Leukemia or Lymphoma Completed NCT00002766 Phase 3
44 Combination Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia Completed NCT00967057 Phase 3
45 Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia Completed NCT00430118 Phase 3
46 Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia Completed NCT00613457 Phase 3
47 Efficacy and Safety of Romidepsin CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma Recruiting NCT01796002 Phase 3
48 Naloxone Hydrochloride Study for Relief of Pruritus in Patients With Mycosis Fungoides (MF) Form of CTCL Recruiting NCT02811783 Phase 3
49 MEDA Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation for Stage IV Natural Killer/T-cell Lymphoma Recruiting NCT02764281 Phase 3
50 MESA Versus ESA in the Treatment of Early Stage NK/T-cell Lymphoma Recruiting NCT02631239 Phase 3

Search NIH Clinical Center for Peripheral T-Cell Lymphoma

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Peripheral T-Cell Lymphoma cell therapies at LifeMap Discovery.

Genetic Tests for Peripheral T-Cell Lymphoma

Anatomical Context for Peripheral T-Cell Lymphoma

MalaCards organs/tissues related to Peripheral T-Cell Lymphoma:

39
T Cells, B Cells, Bone, Bone Marrow, Skin, Liver, Breast

Publications for Peripheral T-Cell Lymphoma

Articles related to Peripheral T-Cell Lymphoma:

(show top 50) (show all 685)
id Title Authors Year
1
Gemcitabine, dexamethasone, and cisplatin (GDP) as salvage chemotherapy for patients with relapsed or refractory peripheral T cell lymphoma-not otherwise specified. ( 27858107 )
2017
2
CD38, BCL-2, PD-1, and PD-1L expression in nodal peripheral T-cell lymphoma: Possible biomarkers for novel targeted therapies? ( 27696517 )
2017
3
Serum ferritin level is a prognostic marker in patients with peripheral T-cell lymphoma. ( 27885817 )
2017
4
Recombinant human endostatin in combination with CHOP regimen for peripheral T cell lymphoma. ( 28053548 )
2017
5
Belinostat for Relapsed or Refractory Peripheral T-Cell Lymphoma. ( 28090369 )
2016
6
Brentuximab vedotin in refractory or relapsed peripheral T-cell lymphomas: the French named patient program experience in 56 patients. ( 26703966 )
2016
7
The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma. ( 27983760 )
2016
8
Primary Uterine Peripheral T-cell Lymphoma: A Case Report of MRI and 18F-FDG PET/CT Findings. ( 27124063 )
2016
9
A phase II study of everolimus (RAD001), an mTOR inhibitor plus CHOP for newly diagnosed peripheral T-cell lymphomas. ( 26861608 )
2016
10
CD1d-restricted peripheral T cell lymphoma in mice and humans. ( 27069116 )
2016
11
First Multicenter, Randomized Phase 3 Study in Patients (Pts) With Relapsed/Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL): Alisertib (MLN8237) Versus Investigatora89s Choice (LUMIERE trial; NCT01482962). ( 27466629 )
2016
12
Lenalidomide in relapsed adult T-cell leukaemia-lymphoma or peripheral T-cell lymphoma (ATLL-001): a phase 1, multicentre, dose-escalation study. ( 26947199 )
2016
13
EBV-associated Peripheral T-Cell Lymphoma of Gastrointestinal Tract Presented With Widespread Chronic Inflammation: A Case Report. ( 27093448 )
2016
14
Dnmt3a Is a Haploinsufficient Tumor Suppressor in CD8+ Peripheral T Cell Lymphoma. ( 27690235 )
2016
15
Comorbidity as an independent prognostic factor in elderly patients with peripheral T-cell lymphoma. ( 27069369 )
2016
16
Prognosis of patients with peripheral T cell lymphoma who achieve complete response after CHOP/CHOP-like chemotherapy without autologous stem cell transplantation as an initial treatment. ( 27928587 )
2016
17
Peripheral T-cell lymphoma of tongue: Report of a rare case and review of literature. ( 27601841 )
2016
18
Discordant lymphoma of duodenal EBV-positive peripheral T-cell lymphoma not otherwise specified and ileal diffuse large B-cell lymphoma. ( 27169448 )
2016
19
Clinical features and treatment outcomes of peripheral T-cell lymphoma in children. A current data report from Polish Pediatric Leukemia/Lymphoma Study Group (PPLLSG). ( 27254421 )
2016
20
Racial Patterns of Peripheral T-Cell Lymphoma Incidence and Survival in the United States. ( 26962200 )
2016
21
Peripheral T-cell lymphoma mimicking Schnitzler syndrome. ( 27321901 )
2016
22
The role of high-dose chemotherapy and autologous stem cell transplant for treatment-naI-ve patients with peripheral T-cell lymphoma: a systematic review of the literature. ( 27146257 )
2016
23
Hemophagocytic lymphohistiocytosis with leukoencephalopathy in a patient with dermatomyositis accompanied with peripheral T-cell lymphoma: a case report. ( 27484255 )
2016
24
Clinical and economic burden of peripheral T-cell lymphoma in commercially insured patients in the United States: findings using real-world claims data. ( 27152635 )
2016
25
A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients. ( 27071522 )
2016
26
Pralatrexate in Combination with Bortezomib for Relapsed or Refractory Peripheral T Cell Lymphoma in 5 Elderly Patients. ( 27366017 )
2016
27
Molecular alterations and tumor suppressive function of the DUSP22 (Dual Specificity Phosphatase 22) gene in peripheral T-cell lymphoma subtypes. ( 27626696 )
2016
28
Effects of first-line chemotherapy on natural killer cells in adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. ( 27289375 )
2016
29
An analysis of MYC and EBV in diffuse large B-cell lymphomas associated with angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma not otherwise specified. ( 26772393 )
2016
30
Integrated mate-pair and RNA sequencing identifies novel, targetable gene fusions in peripheral T-cell lymphoma. ( 27297792 )
2016
31
Development of chidamide for peripheral T-cell lymphoma, the first orphan drug approved in China. ( 27672541 )
2016
32
Clinical and radiological CLIPPERS features after complete remission of peripheral T-cell lymphoma, not otherwise specified. ( 27084205 )
2016
33
Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial. ( 26965915 )
2016
34
Peripheral T-cell lymphoma unspecified type presenting with a pneumothorax as the initial manifestation: A case report and literature review. ( 27313743 )
2016
35
Long-term outcomes of peripheral blood stem cell transplantation for 38 patients with peripheral T-cell lymphoma. ( 28054534 )
2016
36
Long-Term Treatment with Romidepsin in Patients with Peripheral T-Cell Lymphoma. ( 27648317 )
2016
37
GATA3 expression correlates with poor prognosis and tumor-associated macrophage infiltration in peripheral T cell lymphoma. ( 27589565 )
2016
38
A case of peripheral T-cell lymphoma, not otherwise specified in a HCV and HTLV-II-positive patient, diagnosed by abdominal fluid cytology. ( 27034820 )
2016
39
European phase II study of mogamulizumab, an anti-CCR4 monoclonal antibody, in relapsed/refractory peripheral T-cell lymphoma. ( 27418646 )
2016
40
Lymphocytic variant of hypereosinophilic syndrome mimicking peripheral T-cell lymphoma in a young woman. ( 27158718 )
2016
41
Baseline Total Metabolic Tumor Volume measured with fixed or different adaptive thresholding methods equally predicts outcome in Peripheral T cell lymphoma. ( 27754905 )
2016
42
Endoscopic detection of the gastric lesions of peripheral T-cell lymphoma. ( 26981154 )
2016
43
Highly Diverse Efficacy of Salvage Treatment Regimens for Relapsed or Refractory Peripheral T-Cell Lymphoma: A Systematic Review. ( 27711130 )
2016
44
Donor-Derived T-Cell Large Granular Lymphocytic Leukemia in a Patient With Peripheral T-Cell Lymphoma. ( 27496109 )
2016
45
Rapid Fatal Acute Peripheral T-Cell Lymphoma Associated With IgG Plasma Cell Leukemia and IgA Hypergammaglobulinemia. ( 27824644 )
2016
46
Clinical and prognostic differences between ALK-negative anaplastic large cell lymphoma and peripheral T cell lymphoma, not otherwise specified: a single institution experience. ( 27209536 )
2016
47
Durable clinical remission induced by romidepsin for chemotherapy-refractory peripheral T-cell lymphoma with central nervous system involvement. ( 27558082 )
2016
48
Peripheral T-Cell Lymphoma: A Posttransplant Lymphoproliferative Disorder Presenting as a Jejunal Mass in a Renal Transplant Recipient. ( 27915968 )
2016
49
A prospective cohort study of patients with peripheral T-cell lymphoma in the United States. ( 27911989 )
2016
50
Therapeutic options in peripheral T cell lymphoma. ( 27071634 )
2016

Variations for Peripheral T-Cell Lymphoma

Copy number variations for Peripheral T-Cell Lymphoma from CNVD:

7 (show all 12)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 88960 14 9867021 9882729 Gain BCL11B Peripheral t-cell lymphoma
2 88988 14 9896938 9916093 Gain CCNK Peripheral t-cell lymphoma
3 88989 14 9896938 9916093 Gain SETD3 Peripheral t-cell lymphoma
4 217122 7 1 59900000 Gain Peripheral t-cell lymphoma
5 226600 7 59900000 159138663 Gain Peripheral t-cell lymphoma
6 250160 9 2032100 2047878 Loss MLLT3 Peripheral t-cell lymphoma
7 250409 9 2120977 2133626 Loss IFNA17 Peripheral t-cell lymphoma
8 250410 9 2120977 2133626 Loss IFNA5 Peripheral t-cell lymphoma
9 250411 9 2120977 2133626 Loss KLHL9 Peripheral t-cell lymphoma
10 250672 9 2189825 2200141 Loss CDKN2A Peripheral t-cell lymphoma
11 250673 9 2189825 2200141 Loss CDKN2B Peripheral t-cell lymphoma
12 250674 9 2189825 2200141 Loss MTAP Peripheral t-cell lymphoma

Expression for Peripheral T-Cell Lymphoma

Search GEO for disease gene expression data for Peripheral T-Cell Lymphoma.

Pathways for Peripheral T-Cell Lymphoma

Pathways related to Peripheral T-Cell Lymphoma according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1
Show member pathways
11.71 FGFR3 GZMB SYK
2 10.95 ALK FGFR3 SYK
3
Show member pathways
10.94 GZMB NME1
4 10.3 ETV6 GZMB

GO Terms for Peripheral T-Cell Lymphoma

Biological processes related to Peripheral T-Cell Lymphoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 phosphorylation GO:0016310 9.56 ALK FGFR3 NME1 SYK
2 apoptotic process GO:0006915 9.46 CXCR3 FGFR3 GZMB TIA1
3 hippocampus development GO:0021766 9.32 ALK NME1
4 protein autophosphorylation GO:0046777 9.13 ALK FGFR3 SYK
5 peptidyl-tyrosine phosphorylation GO:0018108 8.8 ALK FGFR3 SYK

Molecular functions related to Peripheral T-Cell Lymphoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 kinase activity GO:0016301 9.26 ALK FGFR3 NME1 SYK
2 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.16 ALK FGFR3
3 protein tyrosine kinase activity GO:0004713 8.8 ALK FGFR3 SYK

Sources for Peripheral T-Cell Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....